The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 22: 3501 - 3509

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.22.006

Basic Research

The comparison of ferroptosis characteristics and motor deficits in Parkinson′s disease mouse models

  • Haiyan LI ,
  • Mengzhu LI ,
  • Mengxuan CHEN ,
  • Da GAO ,
  • Kexin DUAN ,
  • Lijun ZHAO ,
  • Meiling ZHU
Expand
  • *.The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine，Shenzhen 518033，Guangdong，China
    *.Department of Clinical Laboratory Medicine，Shenzhen Traditional Chinese Medicine Hospital，Shenzhen 518033，Guangdong，China

Received date: 2025-07-04

  Online published: 2025-11-26

Fold

Abstract

Objective To compare ferroptosis characteristics and motor dysfunction across different mouse models of Parkinson′s disease （PD）. Methods Animal models of PD were divided into five groups： the control group， sham-operated group， 6-hydroxydopamine （6-OHDA） group， 1-methyl-4-phenyl-1，2，3，6-tetrahydropyridine （MPTP） group， and lipopolysaccharide （LPS） group. Differences in ferroptosis-related features and motor dysfunction across these groups were evaluated through behavioral observation， histopathological examination， protein analysis， and assessment of lipid peroxidation and oxidative stress levels. Results In all three model groups， the number of TH-positive neurons in the substantia nigra on the lesioned side was significantly reduced， accompanied by evident neuronal degeneration and a marked decrease in Nissl bodies. Behavioral assessments revealed that the 6-OHDA group displayed the most severe motor deficits. In the substantia nigra， FTH1 protein expression was significantly downregulated in the 6-OHDA， LPS， and MPTP groups （P < 0.01， P < 0.05， P < 0.01）， respectively， while GPX4 expression was also reduced （P < 0.001， P < 0.001， P < 0.01）. Malondialdehyde （MDA） levels were significantly elevated in both the 6-OHDA and MPTP groups （P < 0.05， P < 0.05）. Glutathione （GSH） assays demonstrated markedly reduced levels in the 6-OHDA， MPTP， and LPS groups （P < 0.01， P < 0.001， P < 0.001）. Reactive oxygen species （ROS） detection revealed a significant increase in the MPTP and LPS groups （P < 0.05， P < 0.05）. Conclusion The 6-OHDA model is well suited for studying PD-related behaviors and the underlying mechanisms of motor symptoms， the MPTP model is particularly effective for investigating the ferroptosis pathway， and the LPS model serves as a valuable complement for research on neuroinflammation mechanisms.

Key words： Parkinson′s disease; ferroptosis; 6-OHDA; MPTP; LPS; animal model

Cite this article

Haiyan LI , Mengzhu LI , Mengxuan CHEN , Da GAO , Kexin DUAN , Lijun ZHAO , Meiling ZHU . The comparison of ferroptosis characteristics and motor deficits in Parkinson′s disease mouse models[J]. The Journal of Practical Medicine, 2025 , 41(22) : 3501 -3509 . DOI: 10.3969/j.issn.1006-5725.2025.22.006

References

[1] LI G， MA J， CUI S， et al. Parkinson′s disease in China： A forty-year growing track of bedside work ［J］. Transl Neurodegener， 2019， 8（1）： 22. doi:10.1186/s40035-019-0162-z
[2] SIMOLA N， MORELLI M， CARTA A R. The 6-hydroxydopamine model of Parkinson′s disease ［J］. Neurotox Res， 2007， 11（3/4）： 151-167. doi:10.1007/bf03033565
[3] LIN Z H， LIU Y， XUE N J， et al. Quercetin protects against MPP+/MPTP-induced dopaminergic neuron death in Parkinson′s disease by inhibiting ferroptosis ［J］. Oxid Med Cell Longev， 2022， 2022： 1-17. doi:10.1155/2022/7769355
[4] 周旭， 逯冉冉， 任芳丽， 等. 表没食子儿茶素没食子酸酯通过自噬-溶酶体途径对MPTP诱导帕金森病模型小鼠的作用 ［J］. 实用医学杂志， 2025， 41（8）： 1097-1104.
[5] GU C， WANG F， ZHANG Y， et al. Microglial MT1 activation inhibits LPS-induced neuroinflammation via regulation of metabolic reprogramming ［J］. Aging Cell， 2021， 20（6）： e13375. doi:10.1111/acel.13375
[6] OLIYNYK Z， RUDYK M， DOVBYNCHUK T， et al. Inflammatory hallmarks in 6-OHDA- and LPS-induced Parkinson′s disease in rats ［J］. Brain Behav Immun Health， 2023， 30： 100616. doi:10.1016/j.bbih.2023.100616
[7] TATTON N A， KISH S J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1，2，3，6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining ［J］. Neuroscience， 1997， 77（4）： 1037-1048. doi:10.1016/s0306-4522(96)00545-3
[8] LI S， WANG Z， LIU G， et al. Neurodegenerative diseases and catechins： （-）-epigallocatechin-3-gallate is a modulator of chronic neuroinflammation and oxidative stress ［J］. Front Nutr， 2024， 11： 1425839. doi:10.3389/fnut.2024.1425839
[9] 胡梦妮， 张小蕾， 荣臻， 等. 电针对MPTP诱导帕金森病小鼠FoXO1/NLRP3通路介导神经炎症的影响 ［J］. 实用医学杂志， 2024， 40（11）： 1494-1499. doi:10.3969/j.issn.1006-5725.2024.11.005
[10] DENG I， CORRIGAN F， ZHAI G， et al. Lipopolysaccharide animal models of Parkinson′s disease： Recent progress and relevance to clinical disease ［J］. Brain Behav Immun Health， 2020， 4： 100060. doi:10.1016/j.bbih.2020.100060
[11] PRASAD E M， HUNG S Y. Behavioral tests in neurotoxin-induced animal models of Parkinson′s disease ［J］. Antioxidants， 2020， 9（10）： 1007. doi:10.3390/antiox9101007
[12] BEN-SHLOMO Y， DARWEESH S， LLIBRE-GUERRA J， et al. The epidemiology of Parkinson′s disease ［J］. Lancet， 2024， 403（10423）： 283-292. doi:10.1016/s0140-6736(23)01419-8
[13] TAGUCHI T， IKUNO M， YAMAKADO H， et al. Animal model for prodromal Parkinson′s disease ［J］. Int J Mol Sci， 2020， 21（6）： 1961. doi:10.3390/ijms21061961
[14] BHATTACHARYYA D， BHUNIA A. Gut-Brain axis in Parkinson′s disease etiology： The role of lipopolysaccharide ［J］. Chem Phys Lipids， 2021， 235： 105029. doi:10.1016/j.chemphyslip.2020.105029
[15] JACKSON-LEWIS V， PRZEDBORSKI S. Protocol for the MPTP mouse model of Parkinson′s disease ［J］. Nat Protoc， 2007， 2（1）： 141-151. doi:10.1038/nprot.2006.342
[16] HEO E J， LEE Y， HYUNG SEO M， et al. Association between SGK1 and α-synuclein in skeletal muscle in an MPTP-induced Parkinson′s disease model ［J］. Neurosci Lett， 2023， 814： 137464. doi:10.1016/j.neulet.2023.137464
[17] SONG S， JIANG L， OYARZABAL E A， et al. Loss of brain norepinephrine elicits neuroinflammation-mediated oxidative injury and selective caudo-rostral neurodegeneration ［J］. Mol Neurobiol， 2019， 56（4）： 2653-2669. doi:10.1007/s12035-018-1235-1
[18] MATSUMOTO M， LIU J， IWATA K， et al. NOX1/NADPH oxidase is involved in the LPS-induced exacerbation of collagen-induced arthritis ［J］. J Pharmacol Sci， 2021， 146（2）： 88-97. doi:10.1016/j.jphs.2021.01.009
[19] ISENBRANDT A， COULOMBE K， MORISSETTE M， et al. Three-dimensional analysis of sex- and gonadal status- dependent microglial activation in a mouse model of Parkinson′s disease ［J］. Pharmaceuticals， 2023， 16（2）： 152. doi:10.3390/ph16020152
[20] ZHOU X， GAO Y， WEI J， et al. The intestinal microbiota exerts a sex-specific influence on neuroinflammation in a Parkinson′s disease mouse model ［J］. Neurochem Int， 2024， 173： 105661. doi:10.1016/j.neuint.2023.105661
[21] SUN J， LIN X M， LU D H， et al. Midbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons ［J］. J Clin Invest， 2023， 133（13）： e173110. doi:10.1172/jci173110
[22] WARD R J， ZUCCA F A， DUYN J H， et al. The role of iron in brain ageing and neurodegenerative disorders ［J］. Lancet Neurol， 2014， 13（10）： 1045-1060. doi:10.1016/s1474-4422(14)70117-6
[23] JIANG H， WANG J， ROGERS J， et al. Brain iron metabolism dysfunction in Parkinson′s disease ［J］. Mol Neurobiol， 2017， 54（4）： 3078-3101. doi:10.1007/s12035-016-9879-1
[24] THAKKAR H， CHATTERJEE S， VERMA A， et al. Malondialdehyde mediated alpha-synuclein aggregation： A plausible etiology of Parkinson′s disease in oxidative stress ［J］. Chem Res Toxicol， 2025， 38（4）： 573-582. doi:10.1021/acs.chemrestox.4c00348
[25] BJ?RKLUND G， PEANA M， MAES M， et al. The glutathione system in Parkinson′s disease and its progression ［J］. Neurosci Biobehav Rev， 2021， 120： 470-478. doi:10.1016/j.neubiorev.2020.10.004
[26] PAJARES M， ROJO A I， MANDA G， et al. Inflammation in Parkinson′s disease： Mechanisms and therapeutic implications ［J］. Cells， 2020， 9（7）： 1687. doi:10.3390/cells9071687
[27] AGRAWAL S， KUMARI R， SOPHRONEA T， et al. Design and synthesis of benzo［d］thiazol-2-yl-methyl-4-（substituted）-piperazine-1-carbothioamide as novel neuronal nitric oxide inhibitors and evaluation of their neuroprotecting effect in 6-OHDA-induced unilateral lesioned rat model of Parkinson′s disease ［J］. Biomed Pharmacother， 2022， 156： 113838. doi:10.1016/j.biopha.2022.113838
[28] WANG A， ZHONG G， YING M， et al. Inhibition of NLRP3 inflammasome ameliorates LPS-induced neuroinflammatory injury in mice via PINK1/Parkin pathway ［J］. Neuropharmacology， 2024， 257： 110063. doi:10.1016/j.neuropharm.2024.110063
[29] LI Y， JIANG J， LI J， et al. Exosome‐derived CDC42 from hypoxia‐pretreated neural stem cells inhibits ACSL4‐related ferroptosis to alleviate vascular injury in Parkinson′s disease mice models ［J］. J Neurochem， 2025， 169（3）： e70027. doi:10.1111/jnc.70027
Options
Outlines

/

〈 〉